Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
CD47 (CD47 Molecule)
i
Other names:
CD47, CD47 Molecule, Antigenic Surface Determinant Protein OA3, Leukocyte Surface Antigen CD47, IAP, CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer), Antigen Identified By Monoclonal Antibody 1D8, Integrin Associated Protein, Rh-Related Antigen, CD47 Glycoprotein, MER6, OA3, Integrin-Associated Signal Transducer, Integrin-Associated Protein, Protein MER6, CD47 Antigen
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
961
Associations
(16)
News
Trials
VERI cancer hierarchy
Reset Filters
CD47 overexpression
Triple Negative Breast Cancer
CD47 overexpression
Triple Negative Breast Cancer
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
CD47 overexpression
Glioblastoma
CD47 overexpression
Glioblastoma
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
CD47 overexpression
Ovarian Cancer
CD47 overexpression
Ovarian Cancer
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
CD36 overexpression + CD47 overexpression
Pancreatic Cancer
CD36 overexpression + CD47 overexpression
Pancreatic Cancer
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
VT1021
Sensitive: C3 – Early Trials
VT1021
Sensitive
:
C3
CD47-MET fusion
Lung Adenocarcinoma
CD47-MET fusion
Lung Adenocarcinoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
CD47 overexpression
Solid Tumor
CD47 overexpression
Solid Tumor
VT1021
Sensitive: D – Preclinical
VT1021
Sensitive
:
D
VT1021
Sensitive: D – Preclinical
VT1021
Sensitive
:
D
CD47 overexpression + CD38 underexpression
Multiple Myeloma
CD47 overexpression + CD38 underexpression
Multiple Myeloma
ABBV-IMAB-TJC4 + MOR202
Sensitive: D – Preclinical
ABBV-IMAB-TJC4 + MOR202
Sensitive
:
D
ABBV-IMAB-TJC4 + MOR202
Sensitive: D – Preclinical
ABBV-IMAB-TJC4 + MOR202
Sensitive
:
D
CD47 overexpression
Multiple Myeloma
CD47 overexpression
Multiple Myeloma
BCMA-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
BCMA-targeted CAR-T immunotherapy
Sensitive
:
D
BCMA-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
BCMA-targeted CAR-T immunotherapy
Sensitive
:
D
CD47 expression
Solid Tumor
CD47 expression
Solid Tumor
YH38560
Sensitive: D – Preclinical
YH38560
Sensitive
:
D
YH38560
Sensitive: D – Preclinical
YH38560
Sensitive
:
D
PD-L1 expression + CD47 expression
Colon Cancer
PD-L1 expression + CD47 expression
Colon Cancer
NI-2901
Sensitive: D – Preclinical
NI-2901
Sensitive
:
D
NI-2901
Sensitive: D – Preclinical
NI-2901
Sensitive
:
D
CD47 expression + EPCAM expression
Small Cell Lung Cancer
CD47 expression + EPCAM expression
Small Cell Lung Cancer
VBI-003
Sensitive: D – Preclinical
VBI-003
Sensitive
:
D
VBI-003
Sensitive: D – Preclinical
VBI-003
Sensitive
:
D
CD47 expression + EPCAM expression
Colorectal Cancer
CD47 expression + EPCAM expression
Colorectal Cancer
VBI-003
Sensitive: D – Preclinical
VBI-003
Sensitive
:
D
VBI-003
Sensitive: D – Preclinical
VBI-003
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.